PNOC FOUNDATION, A LEADING NON-PROFIT TO FURTHER ADVANCEMENTS IN PEDIATRIC BRAIN CANCER, ANNOUNCES FDA APPROVAL OF TOVORAFENIB (DAY101) IN PARTNERSHIP WITH PNOC SCIENTIFIC CONSORTIUM AND DAY ONE BIOPHARMACEUTICALS

First And Only FDA-Approved Type Ii Raf Inhibitor For Patients With Relapsed Or Refractory Plgg Harboring A Braf Fusion Or Rearrangement, Or Braf V600 Mutation Made Possible Through PNOC Clinical Trial FOLLOWING SUCCESSFUL FIREFLY-1 TRIAL IN PARTNERSHIP WITH THE PNOC SCIENTIFIC CONSORTIUM…